To the Editor,

MicroRNAs (miRNAs) play important roles in cell proliferation, differentiation, and survival and may be useful for acute myeloid leukemia (AML) diagnosis and prognosis \[[@CR1]--[@CR4]\]. In this study, we defined a novel miRNA, hsa-miR-12462, through small RNA sequencing of the bone marrow (BM) cells from 128 newly diagnosed subjects with AML (Supplementary Table1-2). Based on 2016 World Health Organization (WHO) criteria, all subjects were grouped into 2 cohorts: (1) those achieving a complete remission (CR) with conventional induction chemotherapy and remaining in CR ≥ 6 months and (2) those not achieving CR after 2 courses of standard induction chemotherapy (refractory) or relapsed in \< 6 months after CR (relapsed) \[[@CR5]\]. Small RNA sequencing of these samples revealed different miRNA expression profiles between CR and refractory/relapsed (RR) AML patients \[[@CR6]\]. One miRNA showed the highest differential expression pattern in this analysis. This miRNA has never been reported in the literature. We named this miRNA as hsa-miR-12462 (Figure S1A). Next, we explored the biological activity of hsa-miR-12462 by overexpressing it in AML cells using a lentiviral vector (Figure S1B). The growth rate of the hsa-miR-12462 overexpressing cells was significantly decreased when compared with those of the wild-type and MOCK controls in both U937 and HL-60 cells (Fig. [1](#Fig1){ref-type="fig"}a, Figure S1C). U937 cells were confirmed using an EdU incorporation assay (Figure S1D-E). Fig. 1Overexpression of hsa-miR-12462 inhibits the growth of U937 cells and increases cytarabine sensitivity. **a** Growth rates of U937 wild-type, MOCK-infected, and overexpressing cells (OE vs. MOCK *P* \< 0.0001). **b** Growth inhibition of wild-type, MOCK-infected, and overexpressing U937 AML cells treated with cytarabine (WT vs. OE *P* \< 0.0001; MOCK vs. OE *P* \< 0.0001). **c** Growth inhibition of wild-type, MOCK-infected, and overexpressing U937 cells treated with cytarabine at the IC~50~ of 4 μM (WT vs. OE *P* \< 0.005; MOCK vs. OE *P* \< 0.005). **d**, **e** Percent apoptosis of MOCK-infected and overexpressing U937 AML cells treated with cytarabine by FACS analysis (**e**, OE vs. MOCK *P* \< 0.0001). **f** Representative histograms of cell cycle phases in MOCK-infected and overexpressing U937 cells by FACS analysis. **g** The tumor tissues from the xenograft mouse model injected with wild-type (MOCK) and hsa-miR-12462 overexpressing U937 cells (OE). **h**, **i** Tumor weights (**h**) and sizes (**i**) from mice injected with wild-type and overexpressing U937 cells (MOCK vs. OE 1.11380 ± 0.27820 g vs. 0.16000 ± 0.02266 g, *n* = 6, *P* = 0.0057). **j** Axial anatomic image of mice injected with overexpressing and wild-type U937 cells obtained with 3.0-T MRI. FOV = 64 mm

Treatment of AML cells with cytarabine for up to 48 h resulted in a lower proliferation of the hsa-miR-12462 overexpressing cells when compared with that of the controls (Fig. [1](#Fig1){ref-type="fig"}b, c, Figure S1F-G). The apoptosis rate of the hsa-miR-12462 overexpressing cells was significantly higher than that of the control (Fig. [1](#Fig1){ref-type="fig"}d, e, Figure S1I,L) as well. These differences were not seen in U937 cells (Figure S1H,J) or HL-60 cells (Figure S1K) treated with doxorubicin. We hypothesized that these different responses might reflect the effects of hsa-miR-12462 on the cell cycle. Cell cycle analysis revealed that a greater proportion of hsa-miR-12462-expressing cells were adjusted in G~0~/G~1~ and S-phase when compared with MOCK-transfected cells (Fig. [1](#Fig1){ref-type="fig"}f, Figure S1M).

We further studied the biological behavior of the hsa-miR-12462 overexpressing U937 cells in a subcutaneous xenograft mouse model (Fig. [1](#Fig1){ref-type="fig"}g). Tumor weight and size in the overexpressing cohort were decreased when compared with those of the MOCK-transfected cohort (Fig. [1](#Fig1){ref-type="fig"}h, i). (MOCK vs. OE: *P* = 0.0057). These differences were further confirmed by both magnetic resonance imaging (MRI; Fig. [1](#Fig1){ref-type="fig"}j) and histopathology (Figure S1N-P).

Through RNA-sequencing analysis of hsa-miR-12462 overexpressing and MOCK-transfected U937 cells, 306 genes were identified with differential expressions (Fig. [2](#Fig2){ref-type="fig"}a, S2A). Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were done as well (Figure S2B-C). Enrichment analysis of the KEGG pathway indicates the involvement of the cAMP signaling pathway (Figure S2C) \[[@CR7]\]. In addition, *CCNE1*, *E2F4*, and *TP53* involved in cell cycle regulation were found significantly downregulated in the RNA-sequencing analysis (Figure S2A). Q-RT-PCR analysis of these genes confirmed the results from the RNA-sequencing analysis (Fig. [2](#Fig2){ref-type="fig"}b--d). Combining the data from the MiRDB, an online microRNA database (<http://mirdb.org>) \[[@CR8]\], with the RNA-sequencing results, 15 genes were found to share predicted targets (Fig. [2](#Fig2){ref-type="fig"}e, f) including *SLC9A1*, *ARRB1*, and *CHRNA6* (Fig. [2](#Fig2){ref-type="fig"}g). *SLC9A1* (NHE1), the most common isomer in the Na^+^/H^+^ exchanger family \[[@CR9]\], is important in cell transformation \[[@CR10]\]. β-arrestins (ARRBs) participate in mediating tumor proliferation and inflammation-induced cancer development \[[@CR11]\], whereas nicotinic acetylcholine receptors (CHRNs) are important regulators of tobacco-induced carcinogenesis \[[@CR12]\]. The mRNA and protein levels of *SLC9A1*, *ARRB1*, *and CHRNA6* were inhibited by overexpression of hsa-miR-12462 (Fig. [2](#Fig2){ref-type="fig"}h, i, S2D-E). Using a luciferase 3′UTR reporter assay, we found that hsa-miR-12462 bound exclusively to the 3′UTR of *SLC9A1* in U937 cells (Fig. [2](#Fig2){ref-type="fig"}j; S2F-G). In summary, a higher level of hsa-miR-12462 in AML cells is associated with increased sensitivity to cytarabine chemotherapy via downregulation of *SLC9A1.*Fig. 2hsa-miR-12462 acts via downregulation of *SLC9A1*. **a** Overview of mRNAs in OE and MOCK U937 cells. **b**--**d***CCNE1* (**b**), *TP53* (**c**), and *E2F4* (**d**) transcript expression in wild-type, MOCK-infected, and overexpressing U937 AML cells is shown (**b**, OE vs. MOCK *P* = 0.0001; **c**, OE vs. MOCK *P* = 0.0001; **d**, OE vs. MOCK *P* = 0.0329). Primers were CCNE1 F: AGC GGT AAG AAG CAG AGC AG, R: TTT GAT GCC ATC CAC AGA AA; TP53 F: CCT CAG CAT CTT ATC CGA GTG G, R: TGG ATG GTG GTA CAG TCA GAG C; and E2F4 F: GAG TGG TCC CAT TGA GGT TC, R: GGC AGA GGT GGA GGT GTA G. **e** Venn diagram of differentially expressed genes as determined by RNA-sequencing analysis. **f** Protein-protein interaction network of 15 target genes. **g** Expression of *SLC9A1*, *ARRB1*, and *CHRNA6* in U937 MOCK-infected and overexpressing U937 cells is shown (MOCK vs. OE *P* \< 0.0001). **h** Expression of *SLC9A1* transcript in wild-type, MOCK-infected, and overexpressing U937 cells is shown. **i** Expression of *SLC9A1*, *ARRB1*, and *CHRNA6* in U937 wild-type, MOCK-infected, and overexpressing cells by western blot. GAPDH is used as a control. **j***SLC9A1* is a direct target of hsa-miR-12462 confirmed by luciferase activity. Luciferase constructs containing the 3′UTR of *SLC9A1* or 3′UTR with point mutations
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**Additional file 1: Table S1.** Patient information. **Table S2.** Demographic and AML - related features of the expression level of hsa-miR-12462
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**Additional file 2: Figure S1.** Hsa-miR-12462 inhibits growth of AML both in cell lines and animal models. A.Schematic diagram of the secondary structure of mature hsa-miR-12462.Structure was predicted by MFOLD. B. hsa-miR-12462 transcript expression in Wild-type, MOCK-infected, and Over-expressing U937 cells (OE *vs*. MOCK P = 0.0005). C. Growth rates of HL-60 Wild-type, MOCK-infected and Over-expressing cells (OE *vs*. MOCK P \< 0.0001). D-E. Cell growth of MOCK and Over-expressing U937 OE *vs*. MOCK P = 0.0004) cells as measured by EdU. F. Growth inhibition of Wild-type, MOCK infected and Over-expressing HL-60 cells treated with cytarabine(OE *vs*. MOCK P=0.0428). G. Growth inhibition of Wild-type, MOCK-infected, and Over-expressing HL-60 cells treated with cytarabine at the IC~50~ = 2.9 μM (MOCK *vs*. OE P = 0.0042). H . Growth inhibition rates of Wild-type, MOCK-infected and Over-expressing U937 cells treated with doxorubicin IC~50~ = 6 μM (OE *vs*. MOCK *vs.* WT P \> 0.05). I,L. Percent apoptosis of MOCK infected and Over-expressing HL-60 cells treated with cytarabine by FACS analysis (L, OE *vs*. MOCK P =0.0377). J,K: Apoptosis percentage of MOCK-infected and Over-expressing U937(J) and HL-60(K) cells treated with doxorubicin by FACS analysis.( J:OE *vs*. MOCK P \> 0.05.K:OE *vs*. MOCK P \> 0.05) M. Quantification of cell-cycle phases in MOCK-infected and over-expressing U937 cells by FACS analysis. N. Hematoxylin and eosin (HE) staining and immune histochemistry analyses of hsa-miR-12462 OE and MOCK tumor sections. HE staining magnification: ×20. MPO staining magnification: ×20. Ki-67 staining magnification: ×20.O-P. Percentage of myeloperoxidase (MPO) and Ki-67 expression in OE and MOCK U937 cells (MOCK *vs*. OE: O, P\<0.0001. P, P\<0.0001)
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**Additional file 3: Figure S2.** The downstream targets of hsa-miR-12462. A. Differential expression of selected genes in hsa-miR-12462 OE and MOCK U937cells. B-C. (B) GO and (C) KEGG pathway enrichment analysis of differentially expressed genes after RNA-sequencing in U937 OE/MOCK cells. D-E. Transcript expression of CHRNA6 (D) and ARRB1 (E) in wild-type, MOCK-infected and OE U937 cells is shown. F-G. Luciferase reporter assay showing the 3\'-UTR segments of (F) *ARRB1* and (G) *CHRNA6* do not contain hsa-miR-12462 binding sites. Error bars indicate ± SD; n=3 each. P values were obtained by the two-tailed Student t-test.
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**Additional file 4.** Detailed materials and methods

AML

:   Acute myeloid leukemia

*SLC9A1*

:   Solute carrier family 9 member A1

cAMP

:   Cyclic adenosine monophosphate

*CCNE1*

:   CyclinE1

*E2F2*

:   *E2F* transcription factor 2

*ARRB1*

:   Arrestin beta-1

*CHRNA6*

:   *C*holinergic receptor, nicotinic, alpha 6
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